Display options
Cite
Laraia L, Stokes J, Emery A, et al. High content screening of diverse compound libraries identifies potent modulators of tubulin dynamics. ACS Med Chem Lett. 2014;5(5):598-603doi: 10.1021/ml5000564.
Laraia, L., Stokes, J., Emery, A., McKenzie, G. J., Venkitaraman, A. R., & Spring, D. R. (2014). High content screening of diverse compound libraries identifies potent modulators of tubulin dynamics. ACS medicinal chemistry letters, 5(5), 598-603. https://doi.org/10.1021/ml5000564
Laraia, Luca, et al. "High content screening of diverse compound libraries identifies potent modulators of tubulin dynamics." ACS medicinal chemistry letters vol. 5,5 (2014): 598-603. doi: https://doi.org/10.1021/ml5000564
Laraia L, Stokes J, Emery A, McKenzie GJ, Venkitaraman AR, Spring DR. High content screening of diverse compound libraries identifies potent modulators of tubulin dynamics. ACS Med Chem Lett. 2014 Feb 24;5(5):598-603. doi: 10.1021/ml5000564. eCollection 2014 May 08. PMID: 24900887; PMCID: PMC4027768.
Copy Download .nbib Format: NLM
Share it on

ACS Med Chem Lett. 2014 Feb 24;5(5):598-603. doi: 10.1021/ml5000564. eCollection 2014 May 08.

High content screening of diverse compound libraries identifies potent modulators of tubulin dynamics.

ACS medicinal chemistry letters

Luca Laraia, Jamie Stokes, Amy Emery, Grahame J McKenzie, Ashok R Venkitaraman, David R Spring

Affiliations

  1. Department of Chemistry, University of Cambridge , Cambridge CB2 1EW, U.K. ; MRC Cancer Unit, University of Cambridge , Hutchison/MRC Research Centre, Biomedical Campus, Cambridge CB2 0XZ, U.K.
  2. MRC Cancer Unit, University of Cambridge , Hutchison/MRC Research Centre, Biomedical Campus, Cambridge CB2 0XZ, U.K.
  3. Department of Chemistry, University of Cambridge , Cambridge CB2 1EW, U.K.

PMID: 24900887 PMCID: PMC4027768 DOI: 10.1021/ml5000564

Abstract

Tubulin modulating agents such as the taxanes are among the most effective antimitotic cancer drugs, although resistance and toxicity present significant problems in their clinical use. However, most tubulin modulators are derived from complex natural products, which can make modification of their structure to address these problems difficult. Here, we report the discovery of new antimitotic compounds with simple structures that can be rapidly synthesized, through the phenotypic screening of a diverse compound library for the induction of mitotic arrest. We first identified a compound, which induced mitotic arrest in human cells at submicromolar concentrations. Its simple structure enabled rapid exploration of activity, defining a biphenylacetamide moiety required for activity, A family of analogues was synthesized, yielding optimized compounds that caused mitotic arrest and cell death in the low nanomolar range, comparable to clinically used antimitotic agents. These compounds can be synthesized in 1-3 steps and good yields. We show that one such compound targets tubulin, partially inhibiting colchicine but not vinblastine binding, suggesting that it acts allosterically to the known colchicine-binding site. Thus, our results exemplify the use of phenotypic screening to identify novel antimitotic compounds from diverse chemical libraries and characterize a family of biphenylacetamides (biphenabulins) that show promise for further development.

Keywords: Phenotypic screening; allosteric; antimitotics; colchicine; tubulin

References

  1. Nat Commun. 2014;5:3155 - PubMed
  2. Nat Commun. 2010 Sep 21;1:80 - PubMed
  3. Mol Cancer Ther. 2009 Aug;8(8):2086-95 - PubMed
  4. ACS Med Chem Lett. 2012 Feb 9;3(2):112-117 - PubMed
  5. Nat Rev Drug Discov. 2011 Jun 24;10(7):507-19 - PubMed
  6. Angew Chem Int Ed Engl. 2013 Jan 2;52(1):410-4 - PubMed
  7. Cell Death Dis. 2012 Oct 18;3:e411 - PubMed
  8. J Org Chem. 2007 May 25;72(11):3981-7 - PubMed
  9. Chem Biol. 2011 May 27;18(5):631-41 - PubMed
  10. ACS Med Chem Lett. 2012 Jan 12;3(1):35-38 - PubMed
  11. J Med Chem. 2012 Apr 12;55(7):3425-35 - PubMed
  12. Chem Soc Rev. 2012 Jun 21;41(12):4444-56 - PubMed
  13. J Med Chem. 2012 Aug 23;55(16):7285-9 - PubMed
  14. Org Biomol Chem. 2012 Oct 7;10(37):7545-51 - PubMed
  15. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6793-8 - PubMed
  16. Nat Rev Cancer. 2010 Mar;10(3):194-204 - PubMed
  17. Science. 2000 Mar 17;287(5460):1964-9 - PubMed
  18. Nat Rev Drug Discov. 2010 Oct;9(10):790-803 - PubMed
  19. Cell Death Differ. 2012 Mar;19(3):369-77 - PubMed
  20. Angew Chem Int Ed Engl. 2008;47(15):2808-12 - PubMed
  21. Org Lett. 2005 Apr 28;7(9):1825-8 - PubMed
  22. Chem Soc Rev. 2011 Aug;40(8):4332-45 - PubMed
  23. Nat Chem Biol. 2005 Jul;1(2):74-84 - PubMed
  24. Nat Chem. 2013 Oct;5(10):861-7 - PubMed
  25. Nature. 2004 Mar 11;428(6979):198-202 - PubMed
  26. Nature. 2005 May 26;435(7041):519-22 - PubMed
  27. ChemMedChem. 2010 Apr 6;5(4):529-33 - PubMed
  28. J Am Chem Soc. 2008 Jan 16;130(2):420-1 - PubMed
  29. Nat Chem. 2010 Sep;2(9):735-40 - PubMed
  30. Nat Rev Cancer. 2004 Apr;4(4):253-65 - PubMed
  31. Chemistry. 2012 Mar 12;18(11):3193-8 - PubMed
  32. Chembiochem. 2013 Feb 11;14(3):295-300 - PubMed

Publication Types

Grant support